RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Please see important risk information

RETISERT represents a dramatic advance in the management of chronic noninfectious uveitis affecting the posterior segment of the eye. With RETISERT, uveitis and retina specialists have the means to provide consistent long-term* delivery of a corticosteroid agent, fluocinolone acetonide, precisely where it is needed.

This site is designed to provide information on the drug delivery technology of RETISERT, the surgical procedure required to implant RETISERT, and important efficacy and safety data.

*RETISERT is designed to deliver the drug for approximately 2½ years.

IMPORTANT RISK INFORMATION ABOUT RETISERT
  • Surgical placement of RETISERT is contraindicated in active viral, bacterial, mycobacterial or fungal infections of the eye.
  • Based on clinical trials with RETISERT, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.
  • As with any surgical procedure, there is risk involved. Potential complications accompanying intraocular surgery to place RETISERT into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, temporary decreased visual acuity, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, vitreous loss, wound complication, wound site erythema and wound dehiscence.
  • Following implantation of RETISERT, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.
  • Use of corticosteroids may result in elevated IOP and/or glaucoma. Based on clinical trials with RETISERT, within 3 years post-implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure.
  • Patients should be advised to have ophthalmologic follow-up examinations of both eyes at appropriate intervals following implantation of RETISERT. Physicians should periodically monitor the integrity of the implant by visual inspection.
  • The most frequently reported ocular adverse events in clinical trials with RETISERT occurring in 50-90% of patients included: cataract, increased intraocular pressure, procedural complications and eye pain. Thirty five to forty percent (35-40%) of patients reported ocular/conjunctival hyperemia, reduced visual acuity and conjunctival hemorrhage. The most common non-ocular event reported was headache (>33%).
REFERENCES:

1. Retisert [package insert]. Rochester, NY: Bausch & Lomb Inc; March 2009. 2. Data on file. Bausch & Lomb Incorporated. 3. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88(9):1159-1162. 4. Jabs DA. Treatment of ocular inflammation. Ocul Immunol Inflamm. 2004;12(3):163-168. 5. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126(9):1191-1201. 6. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol. 2007;18(3):235-239. 7. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007;125(11):1478-1485, E1.

Press here for RETISERTPRESCRIBING INFORMATION

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.